Overview This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies Status: Recruiting Trial end date: 2023-10-01 Target enrollment: Participant gender: Summary This is a Phase 1 study of MH048 in patients with selected Relapsed/Refractory B-cell Malignancies. Phase: Phase 1 Details Lead Sponsor: Minghui Pharmaceutical (Shanghai) LTD